<DOC>
	<DOC>NCT01888393</DOC>
	<brief_summary>This study is designed to evaluate the pharmacokinetics (PK) and safety of multiple doses of lumacaftor in combination with ivacaftor in subjects with moderate hepatic impairment.</brief_summary>
	<brief_title>Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Group A: Subjects with Moderate Hepatic Impairment Male and female 18 to 65 years of age (inclusive) Satisfy the criteria for moderate hepatic impairment defined as a Child Pugh total score of 7 to 9 (Child Pugh Class B) at the Screening Visit Willing and able to comply with schedule visits, treatment, laboratory tests, and contraceptive guidelines. Group B: Healthy subjects Male and female 18 to 65 years of age (inclusive) Healthy subjects with no clinically relevant abnormalities identified by a detailed medical history, complete physical examination, including blood pressure and pulse rate measurement, standard 12lead ECG, and clinical laboratory tests Willing and able to comply with schedule visits, treatment, laboratory tests, contraceptive guidelines and other study procedures Group A: Subjects with Moderate Hepatic Impairment History of any illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject Have fluctuating or rapidly deteriorating hepatic function by history or as indicated by significant variations in or worsening of clinical and/or laboratory signs of hepatic impairment within 6 months before the Screening Visit Other causes of hepatic impairment not related to parenchymal disorder and/or disease of the liver Severe hepatic encephalopathy Type 1 diabetes mellitus or evidence of poorly controlled type 2 diabetes Hepatocellular carcinoma, HIV, hepatitis B/C Significant renal dysfunction Solid organ or bone marrow transplantation History of regular alcohol consumption, drug abuse or regular smoking Group B: Healthy subjects History of any illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject History of regular alcohol consumption, drug abuse or regular smoking</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>pharmacokinetics, hepatic impairment</keyword>
</DOC>